Results 61 to 70 of about 8,412,631 (306)

The peculiarities of macroscopic status of the upper gastrointestinal tract mucosa in patients with hepatic and extrahepatic portal hypertension.

Medičnì Perspektivi, 2018
Identification of endoscopic signs of concomitant pathology of the upper gastrointestinal tract allows to determine the tactics of managing patients with different forms of portal hypertension (PG).
Yu. M. Stepanov, N. V. Chaliy, O. V. Simonova   +2 more
doaj   +1 more source

Advances and challenges in cirrhosis and portal hypertension [PDF]

, 2017
Background Liver cirrhosis is the fourth cause of death in adults in Western countries, with complications of portal hypertension being responsible for most casualties.
Annalisa Berzigotti, Berzigotti, Annalisa   +1 more
core   +2 more sources

Bioengineered Exosome‐Loaded Immunomodulatory Bioadhesive Spray Reverses Liver Fibrosis and Metabolic Dysfunction That Triggers Beneficial Gut‐Liver Crosstalk in Chronic Fatty Liver Disease

Advanced Science, EarlyView.
Umbilical cord stem cell‐derived exosomes encapsulated in an immunomodulatory bioadhesive hydrogel spray enable localized therapy, sustained vesicle delivery, macrophage polarization, suppress systemic inflammation, and mitigate glucose and insulin homeostasis impairments in MAFLD.
Triya Saha, Ayushi Mairal, Shreya Mehrotra, Shiv K. Sarin, Ashok Kumar   +4 more
wiley   +1 more source

Immunogenicity and safety of a booster COVID‐19 vaccination in patients with chronic liver disease: A multicenter study

Portal Hypertension & Cirrhosis, 2023
Aim Patients with chronic liver disease (CLD), especially cirrhosis, are at a high risk of severe illness or death from coronavirus disease‐2019 (COVID‐19) and may have a suboptimal immune response to the severe acute respiratory syndrome coronavirus 2 ...
Jitao Wang, Jingwen Ai, Huiling Xiang, Yanliang Zhang, Zhiyun Hou, Qiran Zhang, Jiaojian Lv, Shubo Chen, Chuan Liu, Qianqian Li, Jing Liang, Faren Xie, Shujun Jiang, Nina Zhang, Aiguo Zhang, Xiaolin Lan, Xuying Zhang, Jinlong Li, Dengxiang Liu, Wenchuan Wang, Wei Rao, Zhang Qun, Qiuju Tian, Xiaolong Qi, Wenhong Zhang   +24 more
doaj   +1 more source

Large‐scale Whole‐Exome Sequencing Defines the Protein‐Coding Architecture of Retinal Structure, Visual Function, and Major Blinding Diseases

Advanced Science, EarlyView.
Large‐scale whole‐exome sequencing in 356,982 UK Biobank participants defines the protein‐coding architecture of retinal structure, visual function, and major blinding diseases. Pleiotropic genes, including CFI, C3, and RIOX1, bridge multiple retinal phenotypes, while experimental validation of FYB2 implicates RPE barrier dysfunction, providing ...
Jianqing Li, Yijun Ge, Jingxiao Du, Liu Yang, Bangsheng Wu, Chenyue Hang, Mengxi Shen, Yimin Mao, Ting Zhang, Qiyu Bo, Tianyuan Zhao, Yutian Jiao, Yazhi Wang, Shunxiang Gao, Jieqiong Chen, Junran Sun, Tong Li, Huixun Jia, Yang Dou, Wei Cheng, Xiaoling Wan, Jintai Yu, Xiaodong Sun, Bai Lu   +23 more
wiley   +1 more source

National Consensus on Portal Hypertension Management in Indonesia

Acta Medica Indonesiana, 2022
Portal hypertension is a clinical syndrome that consists of hypersplenism, ascites, gastroesophageal varices, and encephalopathy. This condition is marked by increased portal pressure gradient and may occur with or without liver cirrhosis.
Juferdy Kurniawan, Andri Sanityoso Sulaiman, Cosmas Rinaldi Adithya Lesmana, Putut Bayupurnama, Muhammad Begawan Bestari, Fardah Akil, Rino Alvani Gani, Irsan Hasan   +7 more
doaj   +2 more sources

Research Progress of Noninvasive Evaluation of Portal Hypertension by Blood‐Based Tests

Portal Hypertension & Cirrhosis
Portal hypertension (PH) is a collection of clinical conditions that occur due to an enduring elevation of pressure within the portal venous system, and it is closely linked to the prognosis of liver disease patients. The hepatic venous pressure gradient
Wei Chen, Zhi Li, Xinjie Zhang, Yanan Chen, Shirui Hao, Xiaojuan Wang, Kuopeng Liang, Jian Zhang, Dengxiang Liu, Shubo Chen, Jinlong Li   +10 more
doaj   +1 more source

Non-cirrhotic portal fibrosis

International Journal of Advanced Medical and Health Research, 2014
Portal hypertension occurs commonly in patients with cirrhosis and rarely in those without cirrhosis of liver. The two most important causes of non-cirrhotic portal hypertension are non-cirrhotic portal fibrosis (NCPF) and extrahepatic portal venous ...
Venkatesan Mukta, Kalaimani Sivamani, Lakshmi C Panicker   +2 more
doaj   +1 more source

Proteogenomic Profiling of Idiopathic Pulmonary Arterial Hypertension Identifies Sex‐Differential Proteins and Candidate Therapeutic Targets

Advanced Science, EarlyView.
An integrated proteogenomic analysis of 44,137 predominantly European‐ancestry UK Biobank participants aged 40–69 years identifies 12 robust proteins associated with idiopathic pulmonary arterial hypertension. These proteins define a high‐mortality molecular endotype, support early detection and mortality prediction, reveal sex‐differential proteomic ...
Xinjie Lin, Yangchang Zhang, Yang Pu, Duanke Liu, Tao Lei, Kai Ma, Qiyu He, Zheng Dou, Yuze Liu, Dengyuan Liu, Yinge He, Yanshang Wang, Xiaojiao Zheng, Yanbing Ma, Jianrong Zhou, Weiding Zhai, Binbin Su, Li Chen, Shoujun Li   +18 more
wiley   +1 more source

Whole-course management of interventional treatment in liver cancer patients with portal hypertension

Journal of Interventional Medicine, 2019
Primary liver cancer often occurs in patients with hepatitis and cirrhosis. Some patients have portal hypertension due to cirrhosis, and present with varying degrees of collateral circulation, splenomegaly and hypersplenism, ascites, and liver ...
Zhenkang Qiu, Gui Song Wang, Fei Gao
doaj   +1 more source